Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a report published on Monday morning,Benzinga reports. HC Wainwright currently has a $18.00 price objective on the stock.

Several other equities analysts also recently commented on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Piper Sandler reaffirmed an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, Chardan Capital reduced their target price on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $14.75.

Tenaya Therapeutics Price Performance

NASDAQ:TNYA opened at $3.29 on Monday. The company has a market cap of $260.63 million, a P/E ratio of -2.28 and a beta of 2.34. The firm’s fifty day moving average price is $2.06 and its two-hundred day moving average price is $2.84. Tenaya Therapeutics has a one year low of $1.61 and a one year high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.07. As a group, equities research analysts expect that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TNYA. abrdn plc acquired a new stake in shares of Tenaya Therapeutics during the 3rd quarter worth $1,063,000. Vanguard Group Inc. lifted its position in Tenaya Therapeutics by 16.4% during the first quarter. Vanguard Group Inc. now owns 2,862,916 shares of the company’s stock worth $14,973,000 after purchasing an additional 403,472 shares during the period. RA Capital Management L.P. grew its stake in Tenaya Therapeutics by 4.5% during the first quarter. RA Capital Management L.P. now owns 5,755,050 shares of the company’s stock worth $30,099,000 after buying an additional 247,703 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after buying an additional 226,466 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Tenaya Therapeutics by 144.1% in the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock valued at $488,000 after buying an additional 92,960 shares in the last quarter. Institutional investors own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.